Wormser Freres Gestion Trims Position in Illumina, Inc. (NASDAQ:ILMN)

Wormser Freres Gestion decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 27,551 shares of the life sciences company’s stock after selling 267 shares during the period. Illumina accounts for approximately 2.2% of Wormser Freres Gestion’s portfolio, making the stock its 20th largest holding. Wormser Freres Gestion’s holdings in Illumina were worth $3,715,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Bank of Stockton raised its stake in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares during the period. Stephens Inc. AR raised its stake in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares during the period. Spire Wealth Management raised its stake in shares of Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after acquiring an additional 97 shares during the period. IFP Advisors Inc raised its stake in shares of Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after acquiring an additional 99 shares during the period. Finally, Freedom Investment Management Inc. raised its stake in shares of Illumina by 3.7% in the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock valued at $382,000 after acquiring an additional 101 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Stephens reaffirmed an “overweight” rating and set a $105.00 price target on shares of Illumina in a research note on Tuesday. JPMorgan Chase & Co. dropped their price target on shares of Illumina from $120.00 to $85.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Guggenheim dropped their price target on shares of Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $128.15.

Illumina Stock Down 0.2%

NASDAQ ILMN opened at $80.37 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company’s 50 day simple moving average is $78.14 and its 200 day simple moving average is $109.01. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a market capitalization of $12.72 billion, a P/E ratio of -10.46, a PEG ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the firm earned $0.98 EPS. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Ankur Dhingra bought 6,100 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the transaction, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.